atural killer cell treament for Blood cancer
Phase 2
- Conditions
- Health Condition 1: C920- Acute myeloblastic leukemia
- Registration Number
- CTRI/2019/02/017505
- Lead Sponsor
- Department of Biotechnology India
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Signed and dated written informed consent by start date of Screening visit in accordance with GCP and local legislation
Patients with refractory acute myeloid leukemia planned for allogeneic stem cell transplantation
Any Age
Eastern Cooperative Oncology Group (ECOG) performance score <2 at screening
Life expectancy of 4 â?? 6 weeks
Exclusion Criteria
Hypersensitivity to chemo drugs
Total bilirubin or liver enzymes greater than 3 times the upper limit of normal
HIV infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1-year relapse free survivalTimepoint: At 1 year
- Secondary Outcome Measures
Name Time Method Incidence of acute and chronic graft versus host disease and 1-year overall survivalTimepoint: 30 days, 100 days and at 1 year